You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
長春高新(000661.SZ):百克生物鼻噴流感減毒活疫苗(液體劑型)獲批臨試
格隆匯 03-03 11:53

格隆匯3月3日丨長春高新(000661.SZ)宣佈,公司控股子公司長春百克生物科技股份公司於2021年3月2日收到了國家藥品監督管理局簽發的《藥物臨牀試驗批准通知書》(通知書編號:2021LP00254)。

國家藥品監督管理局審查,2020年12月2日受理的鼻噴流感減毒活疫苗符合藥品註冊的有關要求,同意按照提交的方案開展預防本株病毒引起的流行性感冒的臨牀試驗。

該次獲批開展的藥物臨牀試驗是針對公司已上市凍幹劑型產品凍幹鼻噴流感減毒活疫苗改變至液體劑型所開展的I、II、III期相關專業研究。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account